ARS Pharmaceuticals upgraded by Leerink Partners with a new price target
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
Leerink Partners upgraded ARS Pharmaceuticals from Market Perform to Outperform and set a new price target of $18.00 from $6.00 previously